Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Moderna, Inc. (MRNA) — XLV Health Care · S&P 500 Profile |莫德納公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Moderna, Inc. (MRNA) — Business, History & S&P 500 Profile |莫德納公司介紹

Moderna company profile · mRNA medicines · Spikevax · history · financial snapshot · S&P 500 rank #145 · 莫德納公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 31, 2026
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$88.52B
Oct 31, 2026 · StockAnalysis
S&P 500 WEIGHT
0.13%
Rank #145 · Oct 31, 2026 (Slickcharts)
FY2025 TOTAL REVENUE
$1.94B
−40.0% YoY · COVID franchise fading
FY2025 NET LOSS
−$2.82B
Loss per share $7.26 · narrowed from −$3.56B

SNAPSHOT

TickerMRNA (NASDAQ)
CompanyModerna, Inc.
GICS sector / industryHealth Care (XLV) / Biotechnology
S&P 500 rank (by weight)#145 · 0.13% (Oct 31, 2026)
Sector rank#22 in Health Care (Oct 31, 2026)
Headquarters325 Binney Street, Cambridge, Massachusetts (principal executive offices)
Founded2010 (as ModeRNA Therapeutics, Inc.)
CEOStéphane Bancel (Chief Executive Officer)
EmployeesApproximately 4,700 full-time (Dec 31, 2025, in 18 countries)
Market cap$88.52B (Oct 31, 2026)
SEC filingsEDGAR — CIK 0001682852

WHAT IT DOES

Moderna is a biotechnology company built on messenger RNA (mRNA): synthetic mRNA instructions that teach a patient’s own cells to make a protein — a viral antigen for a vaccine, or a therapeutic protein — and then degrade. The platform’s first proof was Spikevax, the COVID-19 vaccine that went from sequence to emergency authorization in under a year in 2020. FY2025 total revenue was $1.94B, down 40.0% year on year as the COVID franchise faded.

Moderna now has three commercial products: the COVID vaccines Spikevax and mNEXSPIKE (launched commercially in 2025) and mRESVIA, the RSV vaccine for older and at-risk adults approved by the FDA in May 2024. Product sales were $1.82B in FY2025 — COVID-19 products $1.81B and RSV $8M — with the remaining $126M from grants, collaborations, licenses and stand-ready manufacturing arrangements.

The investment question is whether the platform produces a second franchise before the cash runs down. Moderna ended the COVID windfall years with a deep pipeline — 44 treatment and vaccine candidates, 37 in clinical trials by the company’s count — spanning influenza, rare diseases and oncology, including individualized cancer vaccines. FY2025’s net loss narrowed to $2.82B from $3.56B as restructuring cut the cost base.

REVENUE MIX — FY2025 TOTAL REVENUE

SegmentRevenueShareYoY
Product sales — COVID-19$1,810M93.1%
Product sales — RSV$8M0.4%
Grants, collaborations, licenses, stand-ready$126M6.5%
Total revenue$1,944M100%−40.0%
Source: Moderna FY2025 Form 10-K (fiscal year ended Dec 31, 2025), revenue disaggregation. Product sales total $1,818M; other revenue comprises grants $22M, collaboration $13M, license and royalty $11M and stand-ready manufacturing $80M. Shares rounded.

HISTORY

YearMilestone
2010Founded as ModeRNA Therapeutics, Inc., to commercialize mRNA medicines
2018Shares open for trading on NASDAQ on December 7 (ticker MRNA)
2020COVID-19 vaccine developed with Operation Warp Speed support; emergency authorization in December
2024mRESVIA RSV vaccine approved by the FDA in May
2025mNEXSPIKE COVID vaccine launched commercially; total revenue falls 40% as the COVID franchise fades

COMPETITIVE POSITION

  • Platform breadth — one mRNA manufacturing and delivery platform serves vaccines and therapeutics across indications, compressing development timelines versus traditional biologics.
  • COVID cash generation — Spikevax funded the pipeline build-out; the question is whether that funding bridge lasts until a second franchise scales.
  • Pipeline depth — 44 candidates, 37 in clinical trials, spanning flu, RSV, rare diseases and individualized cancer vaccines.
  • Manufacturing control — the Norwood, Massachusetts facility and the Cambridge platform give Moderna end-to-end control of mRNA production.
  • Competition — Pfizer/BioNTech in COVID and RSV, GSK and Sanofi in RSV, and every large pharma’s mRNA programs contest the same indications.

FINANCIAL SNAPSHOT — FY2025

Total revenue$1.94B (−40.0% YoY, vs $3.24B)
Product sales$1.82B (COVID-19 $1.81B, RSV $8M)
Operating loss−$3.07B
Net loss−$2.82B (vs −$3.56B)
Loss per share$7.26 (vs $9.28; basic, diluted equals basic in a loss year)
Operating cash flow$1.87B
EmployeesApproximately 4,700 full-time (Dec 31, 2025)
Fiscal yearEnds Dec 31 (FY2025 ended Dec 31, 2025)
Source: Moderna FY2025 Form 10-K consolidated statements (filed Feb 20, 2026). The company states it incurred net losses in 2025 and 2024 and expects additional losses; figures are losses, shown negative. Operating cash flow of $1.87B is as reported in the filing.

KEY RISKS

  • Continued losses — Moderna states it incurred net losses in 2025 and 2024 and expects more; long-term profitability is not assured.
  • COVID dependence — 93.1% of FY2025 revenue came from COVID-19 products; demand keeps falling as the pandemic recedes.
  • Clinical risk — 37 candidates in trials means 37 chances of failure; a single pivotal miss can move the valuation materially.
  • Competition — Pfizer/BioNTech, GSK and Sanofi contest RSV and COVID, and large pharma mRNA programs contest every new indication.
  • Regulatory and IP — vaccine approvals, recommendations and mRNA patent disputes can change the revenue line abruptly.

WHY IT MATTERS FOR THE S&P 500

Moderna is the index’s mRNA platform bet: at a 0.13% weight and #22 in Health Care, its results track whether mRNA becomes a general drug modality or remains a COVID-era exception.

Its pipeline read-across matters beyond one company: success in flu, RSV or individualized cancer vaccines would validate the platform for the whole field, while failure would re-rate every mRNA name in the index.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 31, 2026 crawl) · StockAnalysis (market cap — Oct 31, 2026 crawl)
FinancialsModerna FY2025 Form 10-K (SEC EDGAR, filed Feb 20, 2026; fiscal year ended Dec 31, 2025)
Sector classificationGICS (Biotechnology) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.
Library noteChart library not yet published: this draft is a text version; the chart overlay follows on data release. No chart data is invented.

FINANCIALS

繁體中文版

公司快照

代碼MRNA(NASDAQ)
公司Moderna, Inc.
GICS 板塊/行業醫療保健(XLV)/生物科技
標普500排名(按權重)#145 · 0.13%(2026 年 10 月 31 日)
板塊內排名醫療保健第 #22(2026 年 10 月 31 日)
總部美國麻薩諸塞州劍橋 Binney Street 325 號(主要行政辦公室)
成立2010 年(原名 ModeRNA Therapeutics, Inc.)
行政總裁Stéphane Bancel(行政總裁)
員工約 4,700 名全職(2025 年 12 月 31 日,遍佈 18 國)
市值$88.52B(2026 年 10 月 31 日)
SEC 申報EDGAR — CIK 0001682852

業務概覽

莫德納是一家以信使核糖核酸(mRNA)為基礎的生物科技公司:合成 mRNA 指令教導患者自身細胞製造一種蛋白質——疫苗的病毒抗原,或治療性蛋白——隨後降解。該平台的首個證明是 Spikevax 新冠疫苗,2020 年從序列到緊急授權不到一年。FY2025 總收入為 $1.94B,同比下降 40.0%,因新冠業務消退。

莫德納現有三款商業產品:新冠疫苗 Spikevax 與 mNEXSPIKE(2025 年商業上市),以及 2024 年 5 月獲 FDA 批准的 RSV 疫苗 mRESVIA。FY2025 產品銷售 $1.82B——新冠產品 $1.81B、RSV $8M——其餘 $126M 來自補助、合作、授權與備便製造安排。

投資問題是平台能否在現金耗盡前產生第二個業務支柱。莫德納在新冠豐收年份結束時擁有深厚的管線——公司統計 44 個治療與疫苗候選藥,其中 37 個已進入臨床試驗——涵蓋流感、罕見病與腫瘤學,包括個體化癌症疫苗。FY2025 淨虧損收窄至 $2.82B(FY2024 為 $3.56B),因重組削減成本基礎。

收入構成 — FY2025 總收入

板塊收入佔比同比
產品銷售 — 新冠$1,810M93.1%
產品銷售 — RSV$8M0.4%
補助、合作、授權、備便製造$126M6.5%
總收入$1,944M100%−40.0%
來源:莫德納 FY2025 Form 10-K(財政年度截至 2025 年 12 月 31 日)收入拆分。產品銷售合計 $1,818M;其他收入包括補助 $22M、合作 $13M、授權與特許 $11M、備便製造 $80M。佔比經四捨五入。

歷史沿革

年份里程碑
2010以 ModeRNA Therapeutics, Inc. 之名成立,致力 mRNA 藥物商業化
201812 月 7 日股票在 NASDAQ 開始交易(代碼 MRNA)
2020在 Operation Warp Speed 支持下開發新冠疫苗;12 月獲緊急授權
20245 月 mRESVIA RSV 疫苗獲 FDA 批准
2025mNEXSPIKE 新冠疫苗商業上市;新冠業務消退,總收入下降 40%

競爭地位

  • 平台廣度——同一 mRNA 製造與遞送平台服務多個適應症的疫苗與治療藥物,比傳統生物製劑壓縮開發時間。
  • 新冠現金生成——Spikevax 資助了管線建設;問題是這座資金橋能否維持到第二個業務支柱成規模。
  • 管線深度——44 個候選藥、37 個已進入臨床試驗,涵蓋流感、RSV、罕見病與個體化癌症疫苗。
  • 製造掌控——麻薩諸塞州 Norwood 設施與劍橋平台令莫德納全程掌控 mRNA 生產。
  • 競爭——輝瑞/BioNTech 在新冠與 RSV、GSK 與 Sanofi 在 RSV,以及各大藥廠的 mRNA 項目爭奪同一批適應症。

財務快照 — FY2025

總收入$1.94B(同比 −40.0%,FY2024 為 $3.24B)
產品銷售$1.82B(新冠 $1.81B、RSV $8M)
營業虧損−$3.07B
淨虧損−$2.82B(FY2024 為 −$3.56B)
每股虧損$7.26(FY2024 為 $9.28;基本每股,虧損年度攤薄等於基本)
經營現金流$1.87B
員工約 4,700 名全職(2025 年 12 月 31 日)
財政年度截至 12 月 31 日(FY2025 截至 2025 年 12 月 31 日)
來源:莫德納 FY2025 Form 10-K 合併報表(2026 年 2 月 20 日申報)。公司稱 2025 與 2024 年皆錄得淨虧損並預期未來仍有虧損;數字為虧損,以負數表示。經營現金流 $1.87B 為申報數字。

主要風險

  • 持續虧損——莫德納稱 2025 與 2024 年皆錄得淨虧損並預期未來仍有虧損;長期盈利並無保證。
  • 新冠依賴——FY2025 收入的 93.1% 來自新冠產品;疫情消退,需求持續下滑。
  • 臨床風險——37 個候選藥在試驗中即 37 次失敗機會;一次關鍵試驗失利即可大幅改變估值。
  • 競爭——輝瑞/BioNTech、GSK 與 Sanofi 爭奪 RSV 與新冠,各大藥廠的 mRNA 項目爭奪每一個新適應症。
  • 監管與知識產權——疫苗批准、接種建議與 mRNA 專利糾紛可突然改變收入。

對標普500的重要性

莫德納是指數中的 mRNA 平台賭注:權重 0.13%、醫療保健第 #22,其業績追蹤 mRNA 能否成為通用藥物模式,抑或只是一次新冠時代的例外。

其管線的啟示超出單一公司:流感、RSV 或個體化癌症疫苗若成功,將為整個領域驗證該平台;若失敗,則會重新評級指數中每一家 mRNA 公司。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 31 日抓取)· StockAnalysis(市值——2026 年 10 月 31 日抓取)
財務莫德納 FY2025 Form 10-K(SEC EDGAR,2026 年 2 月 20 日申報;財政年度截至 2025 年 12 月 31 日)
板塊分類GICS(生物科技),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。
圖庫說明圖表庫尚未發佈:本稿為文字版;圖表於數據放行後補上。不發明圖表數據。

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · MRNA
Data as of Oct 31, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Moody's Corporation (MCO) — XLF Financials · S&P 500 Profile |穆迪介紹Next · EOG Resources, Inc. (EOG) — XLE Energy · S&P 500 Profile |EOG資源介紹

Entered 2026-10-31 04:14 · updated 2026-11-14 23:52 · rev 5